BRPI0509412A - método de tratamento de policondrite ou mononeurite multiplex em mamìferos e artigo industrializado - Google Patents

método de tratamento de policondrite ou mononeurite multiplex em mamìferos e artigo industrializado

Info

Publication number
BRPI0509412A
BRPI0509412A BRPI0509412-7A BRPI0509412A BRPI0509412A BR PI0509412 A BRPI0509412 A BR PI0509412A BR PI0509412 A BRPI0509412 A BR PI0509412A BR PI0509412 A BRPI0509412 A BR PI0509412A
Authority
BR
Brazil
Prior art keywords
multiplex
mammals
mononeuritis
polychondritis
treatment method
Prior art date
Application number
BRPI0509412-7A
Other languages
English (en)
Inventor
Paul G Brunetta
Kathryn L Sewell
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0509412A publication Critical patent/BRPI0509412A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MéTODO DE TRATAMENTO DE POLICONDRITE OU MONONEURITE MULTIPLEX EM MAMìFEROS E ARTIGO INDUSTRIALIZADO". A presente invenção refere-se ao tratamento de policondrite ou mononeurite multiplex em mamífero com quantidade eficaz de anticorpo que se une a CD20, opcionalmente também com outro agente que trate essas disfunções em quantidade eficaz.
BRPI0509412-7A 2004-04-16 2005-04-15 método de tratamento de policondrite ou mononeurite multiplex em mamìferos e artigo industrializado BRPI0509412A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56322704P 2004-04-16 2004-04-16
US56509804P 2004-04-22 2004-04-22
PCT/US2005/012961 WO2005115453A2 (en) 2004-04-16 2005-04-15 Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies

Publications (1)

Publication Number Publication Date
BRPI0509412A true BRPI0509412A (pt) 2007-09-04

Family

ID=35207581

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509412-7A BRPI0509412A (pt) 2004-04-16 2005-04-15 método de tratamento de policondrite ou mononeurite multiplex em mamìferos e artigo industrializado

Country Status (12)

Country Link
US (2) US20060002930A1 (pt)
EP (1) EP1742660A2 (pt)
JP (1) JP2007532680A (pt)
AR (1) AR049021A1 (pt)
AU (1) AU2005247303A1 (pt)
BR (1) BRPI0509412A (pt)
CA (1) CA2562243A1 (pt)
IL (1) IL178553A0 (pt)
NO (1) NO20065252L (pt)
RU (1) RU2006140374A (pt)
TW (1) TW200603828A (pt)
WO (1) WO2005115453A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE311199T1 (de) * 1999-05-07 2005-12-15 Genentech Inc Behandlung von autoimmunkrankheiten mit antagonisten die oberflächenmarker von b zellen binden
US20020058029A1 (en) * 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
PT1692182E (pt) 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
WO2006031370A2 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
EP2345412A1 (en) * 2005-12-02 2011-07-20 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
AU2006329944A1 (en) * 2005-12-09 2007-07-05 Seattle Genetics, Inc. Methods of using CD40 binding agents
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2008034076A2 (en) * 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
CN105315323A (zh) * 2007-10-30 2016-02-10 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2009067699A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for an oxazaphosphorine drug regimen
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US8815242B2 (en) * 2009-05-27 2014-08-26 Synageva Biopharma Corp. Avian derived antibodies
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
CN104928336B (zh) 2009-10-26 2020-05-08 弗·哈夫曼-拉罗切有限公司 用于生产糖基化免疫球蛋白的方法
JP6012473B2 (ja) * 2010-01-11 2016-10-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
WO2019126536A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof
WO2019126133A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
EP4433506A1 (en) 2021-11-16 2024-09-25 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US219818A (en) * 1879-09-23 Improvement in evaporating-pans
US103971A (en) * 1870-06-07 Improvement in mechanical movement
US41847A (en) * 1864-03-08 Improved washing-machine
US136719A (en) * 1873-03-11 Improvement in travelers for spinning-rings
US82172A (en) * 1868-09-15 Frank stanley
US4587A (en) * 1846-06-20 Machine for lasting shoes and boots
US93621A (en) * 1869-08-10 Improvement in wagon s
US197256A (en) * 1877-11-20 Improvement in saw-handles
US197255A (en) * 1877-11-20 Improvement in receivers and stench-traps for street-sewers
US12665A (en) * 1855-04-10 Improvement sssi steam-boilers
US18041A (en) * 1857-08-25 Xwashing-machine
US157108A (en) * 1874-11-24 Improvement in lubricating compounds
US9444A (en) * 1852-12-07 Hot-air furnace
US180292A (en) * 1876-07-25 Improvement in folding chairs
US128468A (en) * 1872-07-02 Improvement in transferring the natural grain of wood
US21781A (en) * 1858-10-12 Improved method o f lighting street-lamps by electricity
US147885A (en) * 1874-02-24 Improvement in the manufacture of halters and bridles
US185796A (en) * 1876-12-26 Improvement in chairs
US25764A (en) * 1859-10-11 Improvement in cultivators
US9427A (en) * 1852-11-23 Whifeletree
US219433A (en) * 1879-09-09 Improvement in grain-binders
US69545A (en) * 1867-10-08 curtis
US58029A (en) * 1866-09-11 Improved window-shade fastening
US133930A (en) * 1872-12-17 Improvement in toy spring-guns
US6404A (en) * 1849-05-01 shaw and ezra gould
US26801A (en) * 1860-01-10 peters
US88664A (en) * 1869-04-06 Improved device tor mowing- away hat
US965963A (en) * 1910-03-10 1910-08-02 Harry E Blanchard Burner for fuel-oils.
US1156066A (en) * 1915-06-18 1915-10-12 John W Dupuy Stove.
IL47062A (en) * 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) * 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5567610A (en) * 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) * 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
IL85746A (en) * 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) * 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
FI941572L (fi) * 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
ATE244763T1 (de) * 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) * 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69303494T2 (de) * 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
JP3194680B2 (ja) * 1994-12-15 2001-07-30 三菱電機株式会社 内燃機関の失火検出装置
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1999002567A2 (en) * 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6242195B1 (en) * 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PL195870B1 (pl) * 1998-08-11 2007-11-30 Biogen Idec Inc Zastosowanie przeciwciała anty-CD20, zastosowanieznakowanego radioaktywnie przeciwciała anty-CD20,zastosowanie przeciwciała anty-CD20 do przygotowania leku zwierającego przeciwciało i chemioterapięoraz zastosowanie przeciwciała anty-CD20 do przygotowania leku zawierającego przeciwciało i szpik kostny
US6224866B1 (en) * 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
DE19930748C2 (de) * 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
NZ581474A (en) * 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
RU2004127458A (ru) * 2002-02-14 2005-10-27 Иммуномедикс, Инк. (Us) Анти-cd20 антитела, их гибридные белки и способы их использования
EP1575514A2 (en) * 2002-07-31 2005-09-21 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
US20040032828A1 (en) * 2002-08-16 2004-02-19 Cellglide Technologies Corp. Service management in cellular networks
KR20110017020A (ko) * 2002-10-17 2011-02-18 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
SI1613350T1 (sl) * 2003-04-09 2009-08-31 Genentech Inc Zdravljenje avtoimunske bolezni pri bolniku z neustreznim odzivom na inhibitor TNF-alfa

Also Published As

Publication number Publication date
US20070031331A1 (en) 2007-02-08
US20060002930A1 (en) 2006-01-05
WO2005115453A3 (en) 2006-03-16
JP2007532680A (ja) 2007-11-15
AU2005247303A1 (en) 2005-12-08
RU2006140374A (ru) 2008-05-27
IL178553A0 (en) 2007-02-11
AR049021A1 (es) 2006-06-21
WO2005115453A2 (en) 2005-12-08
TW200603828A (en) 2006-02-01
CA2562243A1 (en) 2005-12-08
EP1742660A2 (en) 2007-01-17
NO20065252L (no) 2007-01-15

Similar Documents

Publication Publication Date Title
TW200603828A (en) Treatment of disorders
CY1112862T1 (el) Θραυσματα μονοσθενους αντισωματος χρησιμα ως θεραπευτικα
MY147669A (en) Anti-alpha2 integrin antibodies and their uses
PH12015500576A1 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
AR054233A1 (es) Composiciones de anticuerpos igg2
UA97946C2 (ru) Моноклональное антитело, специфически связывающееся с внеклеточным доменом ilt7 человека
DE602004028651D1 (de) Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper
CY1110759T1 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
MY147019A (en) Anti-alpha v beta 6 antibodies
BRPI0413466A (pt) anticorpos igf-1r humanos modificados
ATE389721T1 (de) Agonistische antikörper gegen den thrombopoietinrezeptor und deren therapeutische verwendungen
UA94084C2 (ru) Влагостойкий комплект досок для пола и половое покрытие
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
BR0209792A (pt) Anticorpos para vla-1
DE602005021694D1 (de) Kombinationstherapien gegen multiple toll-like-rezeptoren und ihre verwendung
MA29528B1 (fr) Agents de fixation
WO2005039504A3 (en) Compounds and methods for treating toll-like receptor 2-related diseases and conditions
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
ECSP099658A (es) Anticuerpos anti-esclerostina
DE602004030341D1 (de) Antikörper gegen interleukin-22 und verwendungen dafür
BRPI0416190A (pt) combinações selectivas de inibidor erbb2/anticorpo anti erbb no tratamento do cancro
BRPI0412629A (pt) método de tratamento de disfunção ocular em mamìferos
DE602004026872D1 (de) Anti-hgf-r-antikörper und deren verwendung
BRPI0412265A (pt) uso de calcitonina em osteoartrite
BR0306857A (pt) Dispositivo absorvente com uma cobertura lubrificante

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 5A., 6A. E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2174 DE 04/09/2012.